Compare UIS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | ABEO |
|---|---|---|
| Founded | 1942 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2M | 281.0M |
| IPO Year | N/A | 1980 |
| Metric | UIS | ABEO |
|---|---|---|
| Price | $2.88 | $5.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.88 | ★ $18.20 |
| AVG Volume (30 Days) | 672.3K | ★ 1.2M |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $1,921,000,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $4.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.37 | $3.93 |
| 52 Week High | $7.54 | $7.54 |
| Indicator | UIS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 51.80 |
| Support Level | $2.58 | $5.07 |
| Resistance Level | $2.89 | $5.40 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 87.14 | 54.00 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.